CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,455,560 | -21.5% | 63,980 | -1.0% | 0.02% | -19.4% |
| Q1 2024 | $4,403,477 | +74.5% | 64,605 | +60.3% | 0.03% | +55.0% |
| Q4 2023 | $2,522,905 | +38.1% | 40,302 | +0.1% | 0.02% | +25.0% |
| Q3 2023 | $1,827,401 | -28.5% | 40,260 | +141.2% | 0.02% | -33.3% |
| Q4 2020 | $2,556,000 | +84.9% | 16,695 | +1.0% | 0.02% | +60.0% |
| Q3 2020 | $1,382,000 | +13.8% | 16,525 | 0.0% | 0.02% | +7.1% |
| Q2 2020 | $1,214,000 | +77.2% | 16,525 | +2.3% | 0.01% | +40.0% |
| Q1 2020 | $685,000 | -30.4% | 16,150 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $984,000 | -44.3% | 16,150 | -62.5% | 0.01% | -47.8% |
| Q3 2019 | $1,766,000 | -13.0% | 43,090 | 0.0% | 0.02% | -11.5% |
| Q2 2019 | $2,030,000 | +190.4% | 43,090 | +120.3% | 0.03% | +188.9% |
| Q1 2019 | $699,000 | – | 19,560 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $20,266,383 | 41.94% |
| NEA Management Company, LLC | 1,587,854 | $64,546,265 | 3.63% |
| ARK Investment Management | 7,829,932 | $318,286,736 | 2.76% |
| Nikko Asset Management Americas, Inc. | 4,006,476 | $162,863,249 | 2.35% |
| Valiant Capital Management, L.P. | 228,983 | $9,308,159 | 1.43% |
| CLOUGH CAPITAL PARTNERS L P | 261,700 | $10,638,105 | 1.08% |
| Green Alpha Advisors, LLC | 30,646 | $1,246,000 | 1.04% |
| EFG Asset Management (North America) Corp. | 94,347 | $3,805,014 | 0.86% |
| ARMISTICE CAPITAL, LLC | 1,036,000 | $42,113,400 | 0.74% |
| SG3 Management, LLC | 117,400 | $4,772,310 | 0.69% |